Key challenges in cost-effectiveness analyses of emerging MASLD therapies: adherence, adverse events, cardiometabolic benefits, and age-related uncertainty: Correspondence to editorial on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”
Abstract
Key challenges in cost-effectiveness analyses of emerging MASLD therapies: adherence, adverse events, cardiometabolic benefits, and age-related uncertainty: Correspondence to editorial on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease"
Fields of Study & Subjects
Diabetes Treatment and Management
Parkinson's Disease Mechanisms and Treatments
Lysosomal Storage Disorders Research
Publication details
- Journal / source
- Clinical and Molecular Hepatology
- Publisher
- The Korean Association for the Study of the Liver
- Volume
- 32
- Issue
- 3
- Pages
- e365–e368
- Publication date
- 27 January 2026
- Language
- EN